# Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval - FDA Guidance Document Source: https://www.globalkeysolutions.net/guidances/guidance-document/pathological-complete-response-in-neoadjuvant-treatment-of-high-risk-early-stage-breast-cancer-use-as-an-endpoint-to-support-accelerated-approval/ad15136b-9f37-470e-a814-e84a9756a3ca > FDA guidance document: Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. Issue date: July 29, 2020. Get complete insights and analysis. --- ## Details - Title: Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval - Communication Type: Guidance Document - Product Type: drugs - Office Name: Center for Drug Evaluation and Research - Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c - Issue Date: 2020-07-29 - Last Changed: 2020-07-29 - Docket Number: FDA-2012-D-0432 ## Related Documents - [Premenopausal Women with Breast Cancer: Developing Drugs for Treatment: Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/premenopausal-women-with-breast-cancer-developing-drugs-for-treatment-guidance-for-industry/03f0e242-74ab-4a8e-b4b3-5d5c1d720852) - [Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment: Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/bladder-cancer-developing-drugs-and-biologics-for-adjuvant-treatment-guidance-for-industry/b3fd959c-72c5-4e86-a4a9-5fa31d0ce7b7) - [Male Breast Cancer: Developing Drugs for Treatment: Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/male-breast-cancer-developing-drugs-for-treatment-guidance-for-industry/76829c69-4547-4b3d-bde5-9bf7ef4e1490)